The majority of patients with recurrent cervical cancer are incurable and treatment is based on the type of primary therapy delivered. Only a very small percentage of the patients with recurrent cervical cancer following primary radiotherapy will have central pelvic recurrences that are amenable to surgical resection and curable by pelvic exenteration. These procedures should be undertaken only after the completion of exhaustive attempts to exclude extrapelvic disease.
Cervix Neoplasms/drug therapy/mortality/*surgery ; Female ; Human ; Neoplasm Recurrence, Local/drug therapy/mortality/*surgery ; Pelvic Exenteration/adverse effects/methods

To observe the outcomes of Traditional Chinese Medicine combined with CO_2 laser surgery on the clinical course and serum immunological indexes of Adult onset Recurrent Respiratory Papillomatosis.69 cases of adult recurrent respiratory papilloma patients who enrolled in Beijing Tongren Hospital from September 2014 to March 2016 were divided randomly into two groups.The Chinese medicine surgery group were treated with traditional Chinese medicine combined with CO_2 laser surgery and the surgery group were treated with CO_2 laser surgery alone.All patients were followed up for more than one year.Relapse time and Derkay score were examed and analyzed between two groups before and after treatment.The detection of aperipheral blood immunoglobulin,T cell subsets,percentage of B cell and NK cell and IgG subtype examed every six month.There was no significant difference between two group in Derkay score,lesion recurrence time and the index of immunology before the treatment(>0.05).However,the recurrence time after treatment [(14.11±1.57)months]prolonged than before treatment[(10.85±2.33)months]in the experimental group.The examination of IgG [(1 539.84±388.20)mg/dl],percentage of total T lymphocytes[(85.14±22.24)%],Th cells[(47.34±19.07)%],B lymphocytes[(12.55±5.26)%]in treatment of traditional Chinese medicine was higher than that before treatment of serum IgG [(1 225.14±260.27)mg/dl],T cells [(69.68±11.12)%],Th [(41.97±10.92)%],B lymphocytes[(10.30±5.45)%].The difference was statistically significant(<0.01).The curative effect of traditional Chinese medicine combined with laser surgery for the treatment of adult recurrent respiratory papillomatosis,can effectively prolong the recurrence time of patients,improve their immune cell antiviral ability and be worthy of clinical popularization and application.
Adult ; Humans ; Laser Therapy ; Medicine, Chinese Traditional ; Neoplasm Recurrence, Local ; Papillomavirus Infections ; drug therapy ; immunology ; surgery ; Respiratory Tract Infections ; drug therapy ; immunology ; surgery

Most prostate cancer cases ultimately relapse after a period of initial response to castration therapy and progress to intractable castration-resistant prostate cancer (CRPC). Hardly any therapeutic options currently used can improve the 2- to 3-year survival of the patient. Recently, some new drugs for the treatment of CRPC through various action mechanisms have been approved, and others are in the advanced stage of clinical trial. This review provides an overview of these new therapeutic agents.
Antineoplastic Agents ; therapeutic use ; Humans ; Male ; Neoplasm Recurrence, Local ; Orchiectomy ; Prostatic Neoplasms ; surgery ; Prostatic Neoplasms, Castration-Resistant ; drug therapy ; mortality

Giant cell tumors(GCT) of bone is benign bone tumors with aggressive and osteolytic activity. As traditional treatment of GCT, removal of bone graft is disease with high local recurrence rate, and could reduce local recurrence by auxiliary means. Different surgical methods such as prosthesis replacement, wide resection and En-bloc resection could be selected for different parts of giant cell tumor of bone, based on the lesion location, size, extent of invasion, recurrence rate. For patients with special region of GCT of bone with removed incompletely and high surgical risk expected, arterial embolism could be performed. The application of bisphosphonates and denosumab are mainly used in treating recurrent, refractory, special parts, metastatic giant cell tumor of bone will bring new hope of treatment for giant cell tumor of bone, due to lower the recurrence rate. Chemotherapy is mainly used in the treatment of metastasis and malignant bone tumor. Radiotherapy for recurrent or unresectable bone giant cell tumor can control tumor progression, but there is the possibility of malignancy. While long-term follow-up studies and long-term results of applications of bisphosphonates and denosumab are lacking, new methods and development of new drugs are still be needed to treat patients with giant cell tumor of bone and also bring about more hope.
Bone Neoplasms ; drug therapy ; surgery ; Denosumab ; therapeutic use ; Diphosphonates ; therapeutic use ; Giant Cell Tumor of Bone ; drug therapy ; surgery ; Humans ; Neoplasm Recurrence, Local ; Treatment Outcome

Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Humans ; Lung Neoplasms ; drug therapy ; radiotherapy ; secondary ; surgery ; Molecular Targeted Therapy ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Radiotherapy, Adjuvant ; Survival Rate ; Thymectomy ; methods ; Thymoma ; drug therapy ; radiotherapy ; surgery ; Thymus Neoplasms ; drug therapy ; radiotherapy ; surgery

OBJECTIVETo investigate the outcome of standard treatment in stage III soft tissue sarcomas and the prognostic factors in these patients.

METHODSClinical, pathological, and therapeutic information of 67 patients with stage III soft tissue sarcomas were collected from Tianjin Medical University Cancer Hospital from January 2003 to January 2006. All these patients were treated with the same treatment program. Univariate analysis was performed on surgical margin, tumor sizes, tumor depth, metastasis free interval and neoadjuvant chemotherapy for the main endpoint, overall survival, and second endpoint, distant recurrence free survival (DRFS), the local recurrence rate was also analysed.

RESULTSUnivariate analysis indicated that tumor sizes, depths and metastasis free interval were related to the overall survival. Furthermore, the tumor sizes and the tumor depth were related to DRFS (P < 0.05). However, surgical margin and neoadjuvant chemotherapy showed no effect on the OS and DRFS (P < 0.05). There was no significant difference in local recurrence rate in patients with different surgical margins.

CONCLUSIONSPatients with stage III soft tissue sarcoma might not benefit from wide resection in local control, DRFS, and OS. The tumor size and depth are important prognostic factors for OS. The pulmonary metastasis occurs during adjuvant chemotherapy predicts worse prognosis. Whether or not neoadjuvant chemotherapy improves OS and DRFS needs further prospective study.

Adult ; Aged ; Chemotherapy, Adjuvant ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Prognosis ; Retrospective Studies ; Sarcoma ; diagnosis ; drug therapy ; surgery ; Soft Tissue Neoplasms ; diagnosis ; drug therapy ; surgery ; Survival Rate ; Treatment Outcome

Breast ; surgery ; Breast Neoplasms ; drug therapy ; pathology ; surgery ; Chemotherapy, Adjuvant ; Female ; Humans ; Lymph Node Excision ; Mastectomy, Segmental ; Neoplasm Recurrence, Local ; Treatment Outcome

Adenocarcinoma ; drug therapy ; pathology ; surgery ; Adenoma, Villous ; drug therapy ; pathology ; surgery ; Adult ; Cell Transformation, Neoplastic ; Follow-Up Studies ; Humans ; Male ; Neoplasm Recurrence, Local ; Urinary Bladder Neoplasms ; drug therapy ; pathology ; surgery

A 68-year-old male was admitted due to fatigue and poor appetite and diagnosed pathologically as pancreatic adenocarcinoma with liver metastasis. The tumor marker carbohydrate antigen 199 (CA199) level was 2003.4 U/mL. The patient received two cycles of modified FOLFIRINOX plus immune checkpoint inhibitor (penpulimab). However, the tumor did not shrink and CA199 level was even higher. Anlotinib was added from the 3rd cycle, and the size of primary tumor and metastatic lesions were significantly reduced. Laparoscopic distal pancreatectomy and splenectomy as well as liver metastasis resection was performed. Three cycles of combined therapy were adopted after surgery followed by maintenance therapy with anlotinib plus penpulimab. There was no evidence of tumor recurrence during the follow-up (nearly 19 months since diagnosis).
Male ; Humans ; Aged ; Pancreatic Neoplasms/drug therapy* ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Adenocarcinoma ; Neoplasm Recurrence, Local/surgery* ; Immunotherapy ; Liver Neoplasms/therapy* ; Pancreatectomy

Aged ; CD3 Complex ; metabolism ; Humans ; Immunohistochemistry ; Leukocyte Common Antigens ; metabolism ; Lymphoma, T-Cell, Peripheral ; drug therapy ; metabolism ; pathology ; surgery ; Male ; Neoplasm Invasiveness ; Neoplasm Recurrence, Local ; Thyroid Neoplasms ; drug therapy ; metabolism ; pathology ; surgery